| Gene symbol | MIR132 | Synonyms | MIRN132, miRNA132, mir-132 | Type of gene | ncRNA |
| Chromosome | 17 | Map location | 17p13.3 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | microRNA 132 | ||||
| GTO ID | GTC3013 |
| Trial ID | NCT05350969 |
| Disease | Heart Failure |
| Altered gene | MIR132 |
| Therapeutic/Target gene | Target gene |
| Therapy | ASO |
| Treatment | CDR132L |
| Phase | Phase2 |
| Recruitment status | Recruiting |
| Title | Phase 2, Multicenter, Randomized, Parallel, 3-arm, Placebo-controlled Study to Assess Efficacy and Safety of CDR132L in Patients With Reduced Left Ventricular Ejection Fraction (<= 45%) After Myocardial Infarction |
| Year | 2022 |
| Country | Czechia|Germany|Greece|Hungary|Netherlands|Poland|Spain|United Kingdom |
| Company sponsor | Cardior Pharmaceuticals GmbH |
| Other ID(s) | CDR132L-P2-01|2021-006040-27 |
| Vector information | |||
|
|||
| Cohort1: dose level 1 | |||||||
|
|||||||
| Cohort2: dose level 2 | |||||||
|
|||||||